[COVID-19 induced Stevens-Johnson syndrome]

Area of Science:

• Dermatology
• Infectious Diseases
• Internal Medicine

Background:

• The COVID-19 pandemic has led to a wide range of clinical manifestations and complications.
• While respiratory symptoms are common, mucocutaneous reactions are increasingly reported.
• Understanding the full spectrum of SARS-CoV-2 effects is crucial for effective patient management.

Observation:

• A case report details a patient who developed Stevens-Johnson syndrome (SJS) following a COVID-19 infection.
• Stevens-Johnson syndrome is a severe mucocutaneous adverse drug reaction or drug reaction with eosinophilia and systemic symptoms.
• The patient presented with characteristic SJS symptoms attributed to SARS-CoV-2.

Findings:

• The patient diagnosed with COVID-19-induced Stevens-Johnson syndrome was successfully treated with prednisolone.
• Rapid improvement and recovery were observed within a few days of initiating corticosteroid therapy.
• This case underscores a potential, albeit rare, dermatological complication of SARS-CoV-2 infection.

Implications:

• This case highlights the need to consider COVID-19 as a potential trigger for Stevens-Johnson syndrome.
• Accurate diagnosis is essential to differentiate SJS caused by SARS-CoV-2 from other etiologies.
• Further research into the immunopathogenesis of COVID-19-related mucocutaneous reactions may improve future treatment strategies.